Cargando…
Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases
Treatment options for Ankylosing Spondylitis (AS) are still limited. The T helper cell 17 (Th17) pathway has emerged as a major driver of disease pathogenesis and a good treatment target. Janus kinases (JAK) are key transducers of cytokine signals in Th17 cells and therefore promising targets for th...
Autores principales: | Hammitzsch, Ariane, Chen, Liye, de Wit, Jelle, Al-Mossawi, M. Hussein, Ridley, Anna, Sekine, Takuya, Simone, Davide, Doig, Karen, Skapenko, Alla, Bowness, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199284/ https://www.ncbi.nlm.nih.gov/pubmed/30353145 http://dx.doi.org/10.1038/s41598-018-34026-1 |
Ejemplares similares
-
Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis
por: Chen, Liye, et al.
Publicado: (2016) -
Progress in our understanding of the pathogenesis of ankylosing spondylitis
por: Simone, Davide, et al.
Publicado: (2018) -
GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis
por: Shi, Hui, et al.
Publicado: (2020) -
From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery
por: Nancy, Zaarour, et al.
Publicado: (2021) -
New developments in our understanding of ankylosing spondylitis pathogenesis
por: Voruganti, Aniruddha, et al.
Publicado: (2020)